247 related articles for article (PubMed ID: 35581200)
21. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.
Horvath D; Temperton N; Mayora-Neto M; Da Costa K; Cantoni D; Horlacher R; Günther A; Brosig A; Morath J; Jakobs B; Groettrup M; Hoschuetzky H; Rohayem J; Ter Meulen J
Sci Rep; 2023 Mar; 13(1):4648. PubMed ID: 36944687
[TBL] [Abstract][Full Text] [Related]
22. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization.
Lapuente D; Fuchs J; Willar J; Vieira Antão A; Eberlein V; Uhlig N; Issmail L; Schmidt A; Oltmanns F; Peter AS; Mueller-Schmucker S; Irrgang P; Fraedrich K; Cara A; Hoffmann M; Pöhlmann S; Ensser A; Pertl C; Willert T; Thirion C; Grunwald T; Überla K; Tenbusch M
Nat Commun; 2021 Nov; 12(1):6871. PubMed ID: 34836955
[TBL] [Abstract][Full Text] [Related]
23. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
24. Intranasal boosting with RBD-HR protein vaccine elicits robust mucosal and systemic immune responses.
Chen L; Ren W; Lei H; Wang J; Que H; Wan D; Alu A; Peng D; Fu M; Hong W; Huang Y; Song X; Lu G; Wei X
Genes Dis; 2024 Jul; 11(4):101066. PubMed ID: 38550714
[TBL] [Abstract][Full Text] [Related]
25. Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.
Nguyen KG; Mantooth SM; Vrabel MR; Zaharoff DA
Front Immunol; 2022; 13():858904. PubMed ID: 35592324
[TBL] [Abstract][Full Text] [Related]
26. Gold-Nanostar-Chitosan-Mediated Delivery of SARS-CoV-2 DNA Vaccine for Respiratory Mucosal Immunization: Development and Proof-of-Principle.
Kumar US; Afjei R; Ferrara K; Massoud TF; Paulmurugan R
ACS Nano; 2021 Nov; 15(11):17582-17601. PubMed ID: 34705425
[TBL] [Abstract][Full Text] [Related]
27. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
Kingstad-Bakke B; Lee W; Chandrasekar SS; Gasper DJ; Salas-Quinchucua C; Cleven T; Sullivan JA; Talaat A; Osorio JE; Suresh M
Proc Natl Acad Sci U S A; 2022 May; 119(20):e2118312119. PubMed ID: 35561224
[TBL] [Abstract][Full Text] [Related]
28. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
29. Early protective effect of a ("pan") coronavirus vaccine (PanCoVac) in Roborovski dwarf hamsters after single-low dose intranasal administration.
Abdelaziz MO; Raftery MJ; Weihs J; Bielawski O; Edel R; Köppke J; Vladimirova D; Adler JM; Firsching T; Voß A; Gruber AD; Hummel LV; Fernandez Munoz I; Müller-Marquardt F; Willimsky G; Elleboudy NS; Trimpert J; Schönrich G
Front Immunol; 2023; 14():1166765. PubMed ID: 37520530
[TBL] [Abstract][Full Text] [Related]
30. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice.
Song S; Zhou B; Cheng L; Liu W; Fan Q; Ge X; Peng H; Fu YX; Ju B; Zhang Z
Virol J; 2022 Jan; 19(1):2. PubMed ID: 34983583
[TBL] [Abstract][Full Text] [Related]
31. The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality.
Lobaina Y; Chen R; Suzarte E; Ai P; Huerta V; Musacchio A; Silva R; Tan C; Martín A; Lazo L; Guillén-Nieto G; Yang K; Perera Y; Hermida L
Viruses; 2024 Mar; 16(3):. PubMed ID: 38543783
[TBL] [Abstract][Full Text] [Related]
32. Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine.
Lin YJ; Lin MY; Chuang YS; Liu LT; Kuo TY; Chen C; Ganesan S; Fattom A; Bitko V; Lien CE
Sci Rep; 2022 Jul; 12(1):11369. PubMed ID: 35790783
[TBL] [Abstract][Full Text] [Related]
33. Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice.
Maltseva M; Galipeau Y; Renner TM; Deschatelets L; Durocher Y; Akache B; Langlois MA
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679875
[TBL] [Abstract][Full Text] [Related]
34. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
Nagai M; Moriyama M; Ichinohe T
mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
[TBL] [Abstract][Full Text] [Related]
35. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants.
Wang Z; Zhao Z; Cui T; Huang M; Liu S; Su X; Li G; Song T; Li W; Zhong N; Xu M; Yang X; Huang W
Emerg Microbes Infect; 2022 Dec; 11(1):829-840. PubMed ID: 35230230
[TBL] [Abstract][Full Text] [Related]
36. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
37. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates.
He Q; Mao Q; Peng X; He Z; Lu S; Zhang J; Gao F; Bian L; An C; Yu W; Yang F; Zhou Y; Yang Y; Li Y; Yuan Y; Yan X; Yang J; Wu X; Huang W; Li C; Wang J; Liang Z; Xu M
Signal Transduct Target Ther; 2022 Mar; 7(1):69. PubMed ID: 35241645
[TBL] [Abstract][Full Text] [Related]
39. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH
J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178
[TBL] [Abstract][Full Text] [Related]
40. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
Jeong H; Choi YM; Seo H; Kim BJ
Front Immunol; 2021; 12():637654. PubMed ID: 33732258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
